A large, multi-institution study led by a Brown University physician-scientist could have important implications for the development of new classes of cancer therapeutics.

Diabetes drugs may be doing more than managing blood sugar, they could also shape cancer biology in unexpected ways.

An update from Race Oncology Ltd. ( ($AU:RAC) ) is now available. Racura Oncology has appointed Australian contract research organisation Beyond ...

Lung cancer is the second-most common cancer and the leading cause of cancer death in the United States. Over 80% of lung ...

Lantern showcases two commercially ready, machine learning platforms that have the potential to accelerate drug discovery from months to days and dramatically reduce costs. predictBBB.ai and LBx-AI, ...

In the high-stakes arena of cancer drug development, SU212 was engineered as a safer twist on podophyllotoxin—a toxic killer ...

Starton Holdings plans $40M IPO for cancer drug delivery innovations, but weak IP and limited backing make this a potentially ...

The loss of domvanalimab is the latest in a string of high-profile failures recorded across the biopharma world for the TIGIT ...

By end user, hospitals accounted for about 46% of the total market value. The global breast cancer drugs market, valued at ...

Ionetix, a mid-Michigan cancer treatment company, receives workforce development funding to train employees in advanced drug development technology.

Interrupting one function of a protein that plays a key role in cell signaling could enable the development of new cancer treatments, according to a study led by Dr. Martin Taylor at the Warren Alpert ...